At a glance
ClinicalIndex Comparison RecordN/ACompleted· 704 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·observational·Posted Jan 15, 2025·Updated Jan 15, 2025
In Brief
An observational study for ccRCC. Completed, enrolled 704 participants across 1 site.
Detailed Summary
This retrospective study included 704 patients with ccRCC who underwent radical or partial nephrectomy. Patients were stratified into the LIPI good group and the intermediate/poor (int./poor) group based on dNLR (≥ 3) and LDH (≥ 245 U/L) levels. Propensity score matching (PSM) was used to adjust for baseline differences and minimize selection bias. Kaplan-Meier survival curves and Cox regression models were employed to evaluate the impact of LIPI and other clinical factors on recurrence-free survival (RFS) and overall survival (OS).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsccRCC
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
Primary CompletionSep 2023
First PostedJan 2025
TodayJul 2026
First PostedJan 15, 2025
Enrollment StartNov 1, 2014
Primary CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 1.5 years ago